

Case report

A rare case of adenocarcinoma of ampulla of Vater - A case report

Abstract

Introduction: Periapillary tumors account for approximately 5% of all gastrointestinal cancers, and Vater's papilla. Vater's papilla tumors are the second most common entity of periampillary cancer.

Case report: We present a 69-year-old female patient who presented to the emergency room with symptoms including: jaundice, hyperchromic urine and involuntary weight loss, which she had developed over the preceding three weeks ago. The results of her laboratory tests showed hyperbilirubinemia with predominance of conjugated bilirubin and she had ultrasound scan of her abdomen and pelvis which demonstrated features adjudged to be suggestive of periampillary mass associated with dilated pancreatico-biliary tree. No abdominopelvic lymphadenopathy, no free peritoneal fluid on computed tomography (CT) scan was demonstrated. She underwent Endoscopic Retrograde Cholangio-Pancreatography (ERCP) which revealed a papillary apparatus with a budding, vegetative tumor with infiltration into her duodenum. She underwent exploratory laparotomy and Whipple's pancreaticoduodenectomy. Histopathology examination of the excised surgical specimen revealed Vater's papilla adenocarcinoma. She would be undergoing regular follow-up assessments after she has been discharged from hospital to ascertain her progress following her pancreato-duodenectomy which we had regarded as her treatment of curative intent pursuant to our multi-disciplinary team approach to her treatment

Conclusion: Surgical resection is the only curative treatment for ampullary carcinoma and the standard surgical approach is pancreaticoduodenectomy. In absence of lymph node metastasis and any organ metastasis, it would be envisaged that the patient would have a good five year survival pursuant to her surgery and she would have regular careful follow-up assessments with inclusion of clinical assessments, laboratory test assessments and radiology imaging assessments. .

Keywords: *periampillary cancer; adenocarcinoma; ERCP; pancreaticoduodenectomy; Whipple procedure;*

1. Introduction:

Ampullary cancer of Vater's papilla is classified as periampullary cancer. Periampullary cancers account for 5% of all gastrointestinal cancers, whilst ampullary cancer is rare and does account for 0.2% of the cases [1]. Vater's papilla tumors are the second most common entity of periampullary cancers after pancreatic adenocarcinoma [2]. The ampullary region is a histologically and physiologically complex region where three different structures meet: the common bile duct (CBD), pancreatic duct (PD) and duodenum[3]. Cattel and Pyrtok first reported malignant transformation of an papilla adenoma [4]. In more than 70% of the investigated ampullary carcinoma, tissue samples were found with severe dysplasia [5]. Clinical presentation of ampullary cancer includes vague abdominal pain, jaundice, recurrent pancreatitis, liver enzyme elevation, or uncommon symptoms such as gastrointestinal bleeding or duodenal obstruction [3].

Diagnostic radiology imaging options include: ultrasound scan, computed tomography (CT) scan, magnetic resonance imaging (MRI) scan, endoscopic retrograde cholangiopancreatography (ERCP), and endoscopic ultrasound (EUS) [6]. Definitive diagnosis is made histologically after sampling (ERCP) or resection. Pancreaticoduodenectomy (Whipple procedure) is regarded as the standard treatment for ampullary cancers whereas endoscopic ampullectomy is typically reserved for benign ampullary lesions[3].

Aim

To report a case of a case of adenocarcinoma of Ampulla of Vater.

2. Case report

2.1 Clinical history

A 69-year-old overweight female patient (BMI: 27 kg/m²), who was known to have essential hypertension and hiatus hernia, presented to the emergency room with jaundice, hyperchromic urine and involuntary weight loss (5 kg in the last month), which she had developed over the preceding three weeks. She did not report having abdominal pain, nausea or vomiting. Initially her laboratory test results showed hyperbilirubinemia (TB; 13 mg/dL) with a predominance of conjugated bilirubin (DB; 11 mg/dL); increased gamma-glutamyl transferase (GGT; 421 U/L), alkaline phosphatase (ALP; 192 U/L), mild hepatic cytolysis (ALT; 88 U/L - AST; 74 U/L), mild leukocytosis (WBC; 103/ μ L), hypochromic and microcytic anemia (Hb; 8.9 g/dL) and increased acute phase protein (CRP; 34 mg/dL), (Fibrinogen; 419 mg/dL).

To rule out cholecystitis, cholecystolithiasis or choledocholithiasis, an abdominal ultrasound scan was performed which showed a solid lesion without a posterior shadow cone, without a Doppler signal. Intra and extrahepatic bile ducts were noted to be dilated. She subsequently underwent a computed tomography (CT) scan of her abdomen and pelvis which was reported to have demonstrated an elongated and increased gallbladder (approx. 13/4.5 cm), infundibular cudate cancer, without hyperdense stones. The intra- and extrahepatic bile duct system was reported to be dilated and dilated choledochus was noted that measured up to 2 cm, up to the level of the duodenal papilla, where a spontaneously hypodense mass was seen, iodophilic, relatively well delimited (axial diameter of about 1 cm), which determined the upstream

dilatation of her common bile duct (CBD) with a maximum diameter of 2 cm intrapancreatic and Wirsung duct (0.5 cm) - which raised the suspicion of a Vaterian ampulloma. No abdominopelvic lymphadenopathy, and no free peritoneal fluid was found. Radiological tumor staging was completed with a multi-detector CT scan of the thorax. No remote metastases were found.

Her tumor marker levels were slightly elevated (CA 19-9; 42 U/ml), (CEA; 5 ng/ml). She had Endoscopic Retrograde Cholangio Pancreatography (ERCP) which revealed a papillary apparatus with a budding, vegetative tumor formation and the biopsies of the tumor mass were undertaken and pathology examination of the biopsy specimens revealed a papillary structure with features of adenomatous type, with high-grade dysplasia.

2.2 Surgical treatment

Following the medical investigations and the specialized diagnosis, the undertaking of operation was decided and this operation was subsequently undertaken with the informed consent of the patient: Duodenopancreatectomy (Whipple procedure) was therefore undertaken.

Pathology examination of the pancreato-duodenectomy specimen demonstrated at the ampullary level, malignant tumor proliferation with well-differentiated ADK appearance with tubular pattern, that was associated chronic inflammation affecting the duodenal wall and the tumor was staged pT2-N0-M0-G1 which included stage IB neoplasia according to ampullary tumors classification. The patient postoperative recovered slowly with no untoward effects, with resumption of her digestive tolerance and intestinal transit on the fourth day postoperatively.

3. Discussion

Vater's ampulla cancers are one of the periampullary tumors with more favorable prognosis than others [7]. It has been pointed out that higher resectability rate of the tumor is associated with the better prognosis [8]. The prognostic factors for Vaters ampulla cancers following surgery had been reported to include: jaundice, depth of tumor infiltration, pancreatic invasion lymph node metastasis, perineural invasion tumor and residual tumor status [3]. The undertaking of preoperative biliary drainage in jaundiced patients was stated to be controversial. Patients with total bilirubin level higher than 5 mg/dl just before surgery, demonstrated poorer survival in a Korean study (Choi et al.) and patients without pancreatic invasion had significantly longer survival than those with pancreatic invasion [8]. Although the etiology of ampullary carcinomas was unknown in the majority of cases that had been reported, several conditions had been documented to be associated with this malignancy, mostly in case reports or small series [9]. Familial adenomatous polyposis (FAP) is an important risk factor for the development of ampullary carcinoma [9].

Seventy-five percent of all ampullary neoplasms are adenocarcinomas, 20% are benign adenomas, and 5% are neuroendocrine tumors [9]. Adenocarcinomas account for 90% of ampullary malignancies; the rest the tumors include unusual types, such as mucinous, signet-ring cell, and undifferentiated carcinomas [9]. Histopathologically, 90% of ampullary adenocarcinoma can be classified into pancreaticobiliary or intestinal types [10].

Immunohistochemical analysis these tumors had shown high expression of CEA and CA 19-9 in the tumors [9]. Elevated serum concentrations of CEA and CA 19-9 had been detected in 11% to 29% and 41% to 63% of patients with ampullary carcinomas[11]. Elevations of these serum tumor markers had been associated with tumor recurrence and lower rates of disease-free survival in univariate but not multivariate analyses.

In most cases without infiltration or metastases, surgical resection is recommended-and the recommended surgical resection should entail pancreaticoduodenectomy (Whipple procedure)[3].

Outcomes are good in the absence of lymph node metastases, with 5-year survival rates of 59% to 78% [12]. Considering the fact that our reported patient had absence of lymphatic metastasis and absence of metastasis anywhere else in the body and the tumor was staged pT2-N0-M0-G1, this enabled us to undertake a pancreaticoduodenectomy with the expectation that the patient would have a good prognosis.



Fig.1 ERCP – Periampullary tumor




Fig.2 ERCP – Biopsy of tumor

4. Conclusion

Surgical resection is the only curative treatment for ampullary carcinoma and the standard surgical approach is pancreaticoduodenectomy. In absence of lymph node metastasis and any organ metastasis, prognostic are good at five year after surgery.

Abbreviations:

CT – Computer tomography
ERCP – Endoscopic retrograde cholangiopancreatography
CBD – Common bile duct
PD – Pancreatic duct
MRI – Magnetic resonance imaging
EUS – Endoscopic ultrasound
BMI – Body mass index
TB – Total bilirubin
DB – Direct bilirubin
GGT – Gamma-glutamyl transferase
ALT – Alanine aminotransferase
AST – Aspartate aminotransferase
CRP – C-Reactive Protein
CEA – Carcinoembryonic antigen
CA 19-9 – Carbohydrate antigen 19-9

Statements:

Consent for publication: As the corresponding author, I confirm that the manuscript has been read and approved for submission by all co-authors. **Also declare the role played by each co-author.**

Informed Consent: The informed consent was obtained from the patient for publication and any accompanying images.

Statement of Ethics: The accompanying manuscript does not contain any studies carried out by the authors on humans or animals.

Ethical Approval: The treatment strategy/study protocol was approved by a local tumor board/ethics committee.

References

The writing of the references must be improved with consistency and the referencing style of the journal should be adopted please

- [1] R. Manta *et al.*, “Linear endoscopic ultrasonography vs magnetic resonance imaging in ampullary tumors,” *World J. Gastroenterol.*, vol. 16, no. 44, 2010, doi: 10.3748/wjg.v16.i44.5592.
- [2] A. Romiti, “Tumors of ampulla of Vater: A case series and review of chemotherapy options,” *World J. Gastrointest. Oncol.*, vol. 4, no. 3, 2012, doi: 10.4251/wjgo.v4.i3.60.
- [3] G. Hagleitner and F. A. Fellner, “Ampullary region tumors: A case of an intra-ampullary papillary-tubular neoplasm (IAPN),” *Glob. Imaging Insights*, vol. 5, no. 3, 2020, doi: 10.15761/gii.1000204.
- [4] R. B. CATTELL and L. J. PYRTEK, “Premalignant lesions of the ampulla of Vater.,” *Surg. Gynecol. Obstet.*, vol. 90, no. 1, 1950.
- [5] H. G. Beger, F. Treitschke, F. Gansauge, N. Harada, N. Hiki, and T. Mattfeldt, “Tumor of the ampulla of Vater: Experience with local or radical resection in 171 consecutively treated patients,” *Arch. Surg.*, vol. 134, no. 5, 1999, doi: 10.1001/archsurg.134.5.526.
- [6] J. W. Poley and S. Campos, “Methods and outcome of the endoscopic treatment of ampullary tumors,” *Therapeutic Advances in Gastrointestinal Endoscopy*, vol. 13. 2020, doi: 10.1177/2631774519899786.
- [7] A. Karakatsanis, A. Vezakis, G. Fragulidis, C. Staikou, E. E. Carvounis, and A. Polydorou, “Obstructive jaundice due to ampullary metastasis of renal cell carcinoma,” *World J. Surg. Oncol.*, vol. 11, 2013, doi: 10.1186/1477-7819-11-262.
- [8] S. B. Choi, W. B. Kim, T. J. Song, S. O. Suh, Y. C. Kim, and S. Y. Choi, “Surgical outcomes and prognostic factors for ampulla of vater cancer,” *Scand. J. Surg.*, vol. 100, no. 2, pp. 92–98, 2011, doi: 10.1177/145749691110000205.
- [9] D. H. Adams, *Sleisenger and Fordtran’s Gastrointestinal and Liver Disease*, vol. 47, no. 8. 2007.
- [10] A. Pea *et al.*, “Ampulla of Vater carcinoma: Molecular landscape and clinical implications,” *World Journal of Gastrointestinal Oncology*, vol. 10, no. 11. pp. 370–380, 2018, doi: 10.4251/wjgo.v10.i11.370.
- [11] S. Y. Kau, Y. M. Shyr, C. H. Su, C. W. Wu, and W. Y. Lui, “Diagnostic and prognostic values of CA 19-9 and CEA in periampullary cancers,” *J. Am. Coll. Surg.*, vol. 188, no. 4, pp. 420–425, 1999, doi: 10.1016/S1072-7515(98)00326-3.

- [12] A. K. Narang *et al.*, “Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: The Johns Hopkins Hospital - Mayo Clinic collaborative study,” *Radiat. Oncol.*, vol. 6, no. 1, 2011, doi: 10.1186/1748-717x-6-126.

UNDER PEER REVIEW